Skip to main content

Table 4 Outcomes of the OAB economic model for the base-case scenario

From: Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model

Treatment

Continent at Week 12

Continent at Week 52

QALY gain

Total costs (€)

ICER

Fesoterodine

50.6%

33.08%

0.01014

1,937

-

Tolterodine

40.6%

26.53%

0.00846

2,089

Cost-saving

Solifenacin

47.2%

30.85%

0.00957

1,960

Cost-saving

  1. ICER = Incremental cost-effectiveness ratio
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us